GO
Loading...

GlaxoSmithKline PLC

More

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • LONDON/ GENEVA, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines, as one experimental shot hit a snag in a Swiss clinical trial after some subjects reported joint pains. GAVI, which is funded by governments and the Bill& Melinda Gates Foundation, said it was ready to begin procurement as soon as the...

  • LONDON, Dec 11- GAVI, the global vaccines alliance, said on Thursday it was committing up to $300 million to buy Ebola vaccines and was ready to begin procurement as soon as the World Health Organization recommends one for use. Clinical trials with experimental shots are now underway as experts race to contain an epidemic that has killed more than 6,000 people in...

  • US STOCKS-Futures edge lower after volatile session Wednesday, 10 Dec 2014 | 8:36 AM ET

    *Costco, Toll Brothers post quarterly results. NEW YORK, Dec 10- U.S. stock index futures edged lower on Wednesday, a day after stocks staged an intraday rally to erase a decline of nearly 1.3 percent and end nearly flat. Oil prices have been under pressure from the dollar's strength and OPEC's decision against an output cut, with Brent down more than 40 percent from...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • CHICAGO, Dec 9- The U.S. Department of Health and Human Services on Tuesday offered liability protections to drugmakers rushing to develop Ebola vaccines and urged other countries to follow suit. Health and Human Services Secretary Sylvia Burwell made the announcement as part of the Public Readiness and Emergency Preparedness Act in a move aimed at...

  • The sukuk from the International Finance Facility for Immunization Co, for which the World Bank acts as treasury manager, is a break from the predominantly commercial nature of most Islamic finance transactions. The deal is part of World Bank efforts to adapt sukuk for use in a variety of ethical pursuits, including advising the Dubai government on a funding...

  • LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. Bidders, who had been hoping to clinch a deal before the end of the year,...

  • British drugmaker cutting hundreds of US jobs Thursday, 4 Dec 2014 | 1:16 PM ET

    TRENTON, N.J.— Hundreds of British drugmaker GlaxoSmithKline's 17,000 U.S.-based employees will lose their jobs by the end of next year under the pharmaceutical industry's latest restructuring. GlaxoSmithKline PLC, best known for its widely used asthma inhaler Advair, is making changes worldwide that are meant to produce about $1.6 billion in annual...

  • UPDATE 1-GlaxoSmithKline abandons sale of older drugs Thursday, 4 Dec 2014 | 12:03 PM ET

    LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. People familiar with the situation said last month that several private...

  • GlaxoSmithKline abandons sale of older drugs Thursday, 4 Dec 2014 | 11:28 AM ET

    LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

  • Flu vaccine may be less effective this winter Thursday, 4 Dec 2014 | 10:33 AM ET

    NEW YORK— The flu vaccine may not be very effective this winter, according to U.S. health officials who worry this may lead to more serious illnesses and deaths. Flu season has begun to ramp up, and officials say the vaccine does not protect well against the dominant strain seen most commonly so far this year. Tom Frieden, director of the Centers for Disease Control...

  • Ebola booster vaccine starts first trials in Oxford Thursday, 4 Dec 2014 | 4:25 AM ET

    LONDON, Dec 4- Scientists at Oxford University have launched the first clinical tests of a new Ebola vaccine approach, using a booster developed by Denmark's Bavarian Nordic that may improve the effects of a shot from GlaxoSmithKline. Thirty healthy volunteers in Britain who have already received the experimental Ebola vaccine being developed by GSK and the...

  • Many posts going at North Carolina research site. LONDON, Dec 3- GlaxoSmithKline said on Wednesday it would shed "several hundred" U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging. Many of the jobs lost will be from GSK's Research Triangle Park site in North Carolina...

  • LONDON, Dec 3- GlaxoSmithKline confirmed on Wednesday it would shed several hundred U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging. Many of the jobs lost will be from GSK's Research Triangle Park site in North Carolina as drug research is consolidated in...

  • LONDON, Nov 30- GlaxoSmithKline will this week inform U.S. staff of hundreds of job cuts in its biggest market as the drugmaker starts implementing a major cost-saving programme, sources familiar with the matter said on Sunday. Britain's top drugmaker announced at third-quarter results on Oct. 22 that the new restructuring scheme would save 1 billion pounds in...

  • Ebola vaccine from Glaxo passes early safety test Thursday, 27 Nov 2014 | 1:56 AM ET

    An experimental Ebola vaccine made by GlaxoSmithKline caused no serious side effects, scientists reported on Wednesday.

  • WASHINGTON, Nov 26- Switzerland's Novartis AG has agreed to sell its nicotine patch, Habitrol, in order to win U.S. antitrust approval for a consumer healthcare joint venture with Britain's GlaxoSmithKline, the U.S. Federal Trade Commission said on Wednesday. The deal is part of a three-way transaction unveiled in April, which includes GSK buying Novartis'...

  • Nov 24- BioMarin Pharmaceuticals Inc said it would buy Dutch drug developer Prosensa Holding NV for about $840 million, betting on a drug that has potential to become the first approved treatment for a rare muscle disorder. "Though the asset has risk given the clinical history, we believe the payoff for BioMarin could be substantial given the unmet need...

  • Nov 24- Merck& Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine meant to prevent infection with the Ebola virus. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths. The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of...